A prospectively validated translational meta-model framework for in silico prediction of dose-ranging Phase 2B tuberculosis regimen outcomes
Year: 2026
Type: preprint
Abstract: Over two-thirds of drug candidates fail during mid-stage clinical development primarily due to insufficient efficacy. This challenge is particularly acute in tuberculosis, where new drugs must be evaluated in combination regimens at appropriate doses, and promising earlier findings have not consistently translated into conclusive Phase 2 results. Here we present a translational meta-model framework for quantitative prediction of dose-ranging Phase 2B tuberculosis regimen outcomes that integrates preclinical pharmacology with historically informed patient heterogeneity. We developed the methodology by back-translating four historical trials, followed by prospective validation through blinded predictions in a first-in-patient Phase 2 trial. Updating only drug-specific preclinical data, the validated framework predicts dose-response and performance versus control for novel regimens, with a quantitative efficacy benchmark further informing their treatment-shortening potential. Our platform enables rational regimen design and dose selection 3–4 years before clinical evaluation, de-risking mid-stage tuberculosis drug development, with potential for extension to other diseases.
Source: Research Square
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7236823532
